Pharming Capex To Revenue from 2010 to 2025

PHAR Stock  USD 8.68  0.14  1.64%   
Pharming Group Capex To Revenue yearly trend continues to be relatively stable with very little volatility. Capex To Revenue is likely to drop to 0.01. Capex To Revenue is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. View All Fundamentals
 
Capex To Revenue  
First Reported
2010-12-31
Previous Quarter
0.006863
Current Value
0.00652
Quarterly Volatility
0.52051221
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pharming Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharming Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 19.2 M, Interest Expense of 6.4 M or Selling And Marketing Expenses of 7.4 M, as well as many indicators such as Price To Sales Ratio of 4.16, Dividend Yield of 0.0 or PTB Ratio of 3.92. Pharming financial statements analysis is a perfect complement when working with Pharming Group Valuation or Volatility modules.
  
Check out the analysis of Pharming Group Correlation against competitors.

Latest Pharming Group's Capex To Revenue Growth Pattern

Below is the plot of the Capex To Revenue of Pharming Group NV over the last few years. It is the ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets. Pharming Group's Capex To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharming Group's overall financial position and show how it may be relating to other accounts over time.
Capex To Revenue10 Years Trend
Slightly volatile
   Capex To Revenue   
       Timeline  

Pharming Capex To Revenue Regression Statistics

Arithmetic Mean0.20
Geometric Mean0.04
Coefficient Of Variation265.64
Mean Deviation0.26
Median0.07
Standard Deviation0.52
Sample Variance0.27
Range2.1179
R-Value(0.49)
Mean Square Error0.22
R-Squared0.24
Significance0.06
Slope(0.05)
Total Sum of Squares4.06

Pharming Capex To Revenue History

2025 0.00652
2024 0.006863
2023 0.005968
2022 0.009615
2021 0.0841
2020 0.0721
2019 0.13

About Pharming Group Financial Statements

Pharming Group shareholders use historical fundamental indicators, such as Capex To Revenue, to determine how well the company is positioned to perform in the future. Although Pharming Group investors may analyze each financial statement separately, they are all interrelated. The changes in Pharming Group's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pharming Group's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Capex To Revenue 0.01  0.01 

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.